Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure

European Heart Journal

Volumn 35, Issue 36, 2014, Pages 2468-2476

  Jankowska, Ewa A ^a,b   Kasztura, Monika ^c   Sokolski, Mateusz ^a,b   Bronisz, Marek ^d   Nawrocka, Sylwia ^b   Oleśkowska Florek, Weronika ^d   Zymliński, Robert ^b   Biegus, Jan ^b   Siwołowski, Paweł ^b   Banasiak, Waldemar ^b   Anker, Stefan D ^e,f   Filippatos, Gerasimos ^g   Cleland, John G F ^h   Ponikowski, Piotr ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MILITARY HOSPITAL   (Poland)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^d First Municipal Hospital   (Poland)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Acute heart failure; Hepcidin; Iron status; Mortality; Soluble transferrin receptor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; HEMOGLOBIN; HEPCIDIN; IRON; MINERALOCORTICOID ANTAGONIST; TRANSFERRIN RECEPTOR; URIC ACID; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RATE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; URIC ACID BLOOD LEVEL; ACUTE DISEASE; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; DEFICIENCY; EPIDEMIOLOGY; HEART FAILURE; METABOLISM; MULTICENTER STUDY; POLAND; PREVALENCE; RISK FACTOR;

ACUTE DISEASE; AGED; ANALYSIS OF VARIANCE; FEMALE; HEART FAILURE; HEPCIDINS; HUMANS; IRON; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POLAND; PREVALENCE; PROSPECTIVE STUDIES; RECEPTORS, TRANSFERRIN; RISK FACTORS;

EID: 84923680702     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu235     Document Type: Article

References (39)

1. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;8:2.
2. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131(Suppl. 2):568S-580S.
3. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013;34:816-829.
4. Datz C, Felder TK, Niederseer D, Aigner E. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest 2013;43:215-224.
5. Ponikowska B, Suchocki T, Paleczny B, Olesinska M, Powierza S, Borodulin-Nadzieja L, Reczuch K, von Haehling S, Doehner W, Anker SD, Cleland JG, Jankowska EA. Iron status and survival in diabetic patients with coronary artery disease. Diabetes Care 2013;36:4147-4156.
6. Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, BanasiakW, von Haehling S, Macdougall IC,Weiss G, McMurray JJ, Anker SD, Gheorghiade M, Ponikowski P. Iron status in patients with chronic heart failure. Eur Heart J 2013;34:827-834.
7. OkonkoDO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation toanemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:1241-1251.
8. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-1880.
9. Kasner M, Aleksandrov AS, Westermann D, Lassner D, Gross M, von Haehling S, Anker SD, Schultheiss HP, Tschöpe C. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction. Int J Cardiol 2013;168: 4652-4657.
10. Ingwall JS. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009; 81:412-419.
11. Neubauer S. The failing heart-An engine out of fuel. N Engl J Med 2007;356: 1140-1151.
12. Soukoulis V, Dihu JB, Sole M, Anker SD, Cleland J, Fonarow GC, Metra M, Pasini E, Strzelczyk T, Taegtmeyer H, Gheorghiade M. Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol 2009;54:1660-1673.
13. Munoz M, Garciá-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol 2011;64:281-286.
14. HentzeMW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010;142:24-38.
15. Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, Roger SD, Savoia HF, Tampi R, Thomson AR, Wood EM, Robinson KL. Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust 2010; 193:525-532.
16. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006;1(Suppl. 1):S4-S8.
17. Kemna EH, Tjalsma H, Willems HL, SwinkelsDW. Hepcidin: from discovery to differential diagnosis. Haematologica 2008;93:90-97.
18. Franchini M, Montagnana M, Lippi G. Hepcidin and iron metabolism: from laboratory to clinical implications. Clin Chim Acta 2010;411:1565-1569.
19. Koulaouzidis A, Said E, Cottier R, Saeed AA. Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis 2009; 18:345-352.
20. Skikne BS. Serum transferrin receptor. Am J Hematol 2008;83:872-885.
21. Rumjon A, Bansal SS, Malyszko J, Macdougall IC. Intra-individual variability of hepcidin in haemodialysis patients using mass spectrometry and ELISA. J Amer Soc Nephrol 2011;22(Suppl. A):481A-482A.
22. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.
23. Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I, Ponikowski P, Anker SD. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 2013;15:1267-1276.
24. OkonkoDO,Grzeslo A, WitkowskiT, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008; 51:103-112.
25. Blanc B, Finch CA, Hallberg L. Nutritional anaemias. Report of a WHO scientific group. WHO Tech Rep Ser 1968;405:1-40.
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130: 461-470.
27. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005;92:965-970.
28. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
29. Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol 2011;58:474-480.
30. Leszek P, Sochanowicz B, Szperl M, Kolsut P, Brzóska K, PiotrowskiW, Rywik TM, Danko B, Polkowska-Motrenko H, Róz?ański JM, Kruszewski M. Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol 2012;159:47-52.
31. Nagao M, Matsuo Y, Kamitani T, Yonezawa M, Yamasaki Y, Kawanami S, Abe K, Mukai Y, Higo T, Yabuuchi H, Takemura A, YoshiuraT, Sunagawa K, Honda H. Quantification of myocardial iron deficiency in nonischemic heart failure by cardiac T2 magnetic resonance imaging. Am J Cardiol 2014;113:1024-1030.
32. Walter PB, Knutson MD, Paler-Martinez A, Lee S, Xu Y, Viteri FE, Ames BN. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proc Natl Acad Sci USA 2002;99:2264-2269.
33. Dong F, Zhang X, Culver B, Chew HG Jr., Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005;109:277-286.
34. Galy B, Ferring-Appel D, Sauer SW, Kaden S, Lyoumi S, Puy H, Kö lker S, Gröne HJ, Hentze MW. Iron regulatory proteins secure mitochondrial iron sufficiency and function. Cell Metab 2010;12:194-201.
35. Riegersperger M,Covic A, Goldsmith D. Allopurinol, uric acid, and oxidative stress in cardiorenal disease. Int Urol Nephrol 2011;43:441-449.
36. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2011;8:92-103.
37. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L; Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15: 808-817.
38. Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, Metra M, Lucci D, Gonzini L, Cirrincione V, Montagna L, Di Lenarda A, Maggioni AP, Tavazzi L; IN HF Outcome Investigators. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol 2014;173:163-169.
39. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.